pharmaphorum16h
GSK rides out vaccine sales weakness with cancer, HIV gains
GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...
Business Times21h
GSK plans £2 billion share buyback, boosts long-term outlook
GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...
FiercePharma15h
Moderna picks Merck KGaA, Roivant alum as marketing chief
As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...
GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...
Should we be worried about bird flu, the 'unpredictable shape-shifter?'
Bird flu has decimated poultry flocks and infected cattle herds. The risk to humans is currently low, but that could easily ...
El Mundo on MSN19h
These are the 11 new best-selling drugs that will transform Medicine in 2025
The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...
Goldman Sachs cuts Pfizer stock price target to $32 from $33
The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...